Great Point Partners LLC trimmed its stake in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 13.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,128,773 shares of the company's stock after selling 343,415 shares during the quarter. ABIVAX Société Anonyme makes up about 7.2% of Great Point Partners LLC's portfolio, making the stock its 2nd largest holding. Great Point Partners LLC owned about 3.36% of ABIVAX Société Anonyme worth $24,523,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its stake in shares of ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after purchasing an additional 5,900 shares in the last quarter. Kennedy Capital Management LLC boosted its position in ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company's stock worth $1,718,000 after buying an additional 31,331 shares during the period. abrdn plc grew its holdings in ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company's stock worth $3,645,000 after acquiring an additional 198,225 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company's stock valued at $12,113,000 after acquiring an additional 131,414 shares during the period. Institutional investors own 47.91% of the company's stock.
ABIVAX Société Anonyme Price Performance
Shares of ABVX stock traded up $0.06 during trading hours on Wednesday, hitting $8.56. 71,783 shares of the company's stock traded hands, compared to its average volume of 94,050. ABIVAX Société Anonyme has a 12 month low of $8.23 and a 12 month high of $17.02. The stock's 50 day simple moving average is $10.17 and its 200 day simple moving average is $11.82.
About ABIVAX Société Anonyme
(
Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Featured Stories
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
